| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Taro Kishi, Hiroshi Nakamura, Tadafumi Kato, Nakao Iwat. A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression. Neuropsychopharmacology reports. 2023-01-12. PMID:36632763. |
a diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression. |
2023-01-12 |
2023-08-14 |
Not clear |
| Taro Kishi, Hiroshi Nakamura, Tadafumi Kato, Nakao Iwat. A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression. Neuropsychopharmacology reports. 2023-01-12. PMID:36632763. |
reported results of a 6-week, double-blind, randomized, placebo-controlled trial of lurasidone in adults with bipolar depression (bdep). |
2023-01-12 |
2023-08-14 |
Not clear |
| Valerio Ricci, Giovanni Martinotti, Domenico De Berardis, Giuseppe Main. Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report. International journal of environmental research and public health. vol 19. issue 23. 2022-12-11. PMID:36498129. |
recently, lurasidone was also extended fda approval for adults with major depressive episodes associated with bipolar i disorder (bipolar depression), as either a monotherapy or as adjunctive therapy with lithium or valproate. |
2022-12-11 |
2023-08-14 |
Not clear |
| Xiangyuan Diao, Dan Luo, Dandan Wang, Jianbo Lai, Qunxiao Li, Peifen Zhang, Huimin Huang, Lingling Wu, Shaojia Lu, Shaohua H. Lurasidone versus Quetiapine for Cognitive Impairments in Young Patients with Bipolar Depression: A Randomized, Controlled Study. Pharmaceuticals (Basel, Switzerland). vol 15. issue 11. 2022-11-24. PMID:36422533. |
lurasidone versus quetiapine for cognitive impairments in young patients with bipolar depression: a randomized, controlled study. |
2022-11-24 |
2023-08-14 |
human |
| Manpreet K Singh, Cynthia Siu, Michael Tocco, Andrei Pikalov, Antony Loebe. Sleep Disturbance and Bipolar Depression in Youth. Current neuropharmacology. 2022-09-29. PMID:36173066. |
the effects of these bridge symptoms on the response to lurasidone 20-80 mg/d compared to placebo treatment was analyzed in children and adolescents with bipolar i depression in a six-week, placebo-controlled, double-blind study followed by a 2-year, open- label extension study of lurasidone. |
2022-09-29 |
2023-08-14 |
Not clear |
| Manpreet K Singh, Cynthia Siu, Michael Tocco, Andrei Pikalov, Antony Loebe. Sleep Disturbance and Bipolar Depression in Youth. Current neuropharmacology. 2022-09-29. PMID:36173066. |
a ggreater improvement in overall depression severity at week 6 with lurasidone (vs. placebo) treatment was observed in the presence (vs. absence) of a"decreased need for sleep" at the baseline, mediated in part by significant reductions from study baseline in a"decreased need for sleep" and manic symptom severity. |
2022-09-29 |
2023-08-14 |
Not clear |
| Jolanta Orzelska-Górka, Joanna Mikulska, Anna Wiszniewska, Grażyna Biał. New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. International journal of molecular sciences. vol 23. issue 18. 2022-09-23. PMID:36142523. |
the purpose of this review presents the background and evidence for the use of the new second/third-generation antipsychotics (aripiprazole, cariprazine, lurasidone, asenapine, brexpiprazole, lumateperone, pimavanserin) in treatment of schizophrenia and depression. |
2022-09-23 |
2023-08-14 |
Not clear |
| Yoshikazu Takaesu, Minoru Takeshima, Koichiro Watanab. Effectiveness and Tolerability of Lurasidone for Bipolar Types I and II and Other Specified Bipolar Depression: A 12-Week Observational Study. Journal of clinical psychopharmacology. 2022-08-02. PMID:35916577. |
effectiveness and tolerability of lurasidone for bipolar types i and ii and other specified bipolar depression: a 12-week observational study. |
2022-08-02 |
2023-08-14 |
Not clear |
| Yoshikazu Takaesu, Minoru Takeshima, Koichiro Watanab. Effectiveness and Tolerability of Lurasidone for Bipolar Types I and II and Other Specified Bipolar Depression: A 12-Week Observational Study. Journal of clinical psychopharmacology. 2022-08-02. PMID:35916577. |
this retrospective chart review study aimed to examine the effectiveness and tolerability of lurasidone for use in patients with bipolar depression. |
2022-08-02 |
2023-08-14 |
Not clear |
| Octavian Vasili. Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents. Frontiers in pharmacology. vol 13. 2022-07-18. PMID:35847011. |
glutamatergic neurotransmission is explored based on the positive results obtained by intranasal esketamine, with subanesthetic intravenous doses of ketamine, and d-cycloserine, traxoprodil, mk-0657, axs-05, avp-786, combinations of cycloserine and lurasidone, or dextromethorphan and quinidine, explored as therapeutic options for mono- or bipolar depression. |
2022-07-18 |
2023-08-14 |
Not clear |
| Carole Dembek, Qi Fan, Xiaoli Niu, Yongcai Mao, Vamshi Ruthwik Anupindi, Kimberly Laubmeier, Michael Tocc. Impact of lurasidone on health-related quality of life in adults with bipolar depression: a post-hoc analysis. Current medical research and opinion. 2022-06-14. PMID:35699377. |
impact of lurasidone on health-related quality of life in adults with bipolar depression: a post-hoc analysis. |
2022-06-14 |
2023-08-14 |
Not clear |
| Carole Dembek, Qi Fan, Xiaoli Niu, Yongcai Mao, Vamshi Ruthwik Anupindi, Kimberly Laubmeier, Michael Tocc. Impact of lurasidone on health-related quality of life in adults with bipolar depression: a post-hoc analysis. Current medical research and opinion. 2022-06-14. PMID:35699377. |
the objective of this post-hoc analysis was to assess the impact of lurasidone monotherapy on health-related quality of life (hrqol) in adults with bipolar depression. |
2022-06-14 |
2023-08-14 |
Not clear |
| Xiaoli Niu, Carole Dembek, Qi Fan, Yongcai Mao, Victoria Divino, Steven Burch, Michael Tocc. The impact of lurasidone on functioning and indirect costs in adults with bipolar depression: a post-hoc analysis. Journal of medical economics. 2022-01-17. PMID:35037813. |
the impact of lurasidone on functioning and indirect costs in adults with bipolar depression: a post-hoc analysis. |
2022-01-17 |
2023-08-13 |
Not clear |
| Xiaoli Niu, Carole Dembek, Qi Fan, Yongcai Mao, Victoria Divino, Steven Burch, Michael Tocc. The impact of lurasidone on functioning and indirect costs in adults with bipolar depression: a post-hoc analysis. Journal of medical economics. 2022-01-17. PMID:35037813. |
the aim of this post-hoc analysis was to assess the impact of lurasidone monotherapy on functional impairment, productivity, and associated indirect costs in patients with bipolar depression. |
2022-01-17 |
2023-08-13 |
Not clear |
| Taro Kishi, Hiroshi Nakamura, Nakao Iwat. Differences in the incidence of lurasidone adverse events between depressive disorders and schizophrenia in double-blind, randomized, placebo-controlled trials: a meta-analysis. Psychopharmacology. vol 238. issue 12. 2021-11-30. PMID:34476565. |
we conducted a meta-analysis of double-blind, randomized placebo-controlled trials of lurasidone (lur) to examine the difference in the risk ratios (rrs) for adverse events (aes) between depressive disorders (bipolar depression and major depressive disorders) and schizophrenia. |
2021-11-30 |
2023-08-13 |
Not clear |
| Jun Ishigooka, Tadafumi Kato, Mari Miyajima, Kei Watabe, Takahiro Masuda, Katsuhiko Hagi, Teruhiko Higuch. Corrigendum to "Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study". [Journal of Affective Disorders 281 (2021) 160-167]. Journal of affective disorders. vol 297. 2021-11-29. PMID:34548154. |
corrigendum to "lurasidone in the long-term treatment of bipolar i depression: a 28-week open label extension study". |
2021-11-29 |
2023-08-13 |
Not clear |
| Melissa P DelBello, Michael Tocco, Andrei Pikalov, Ling Deng, Robert Goldma. Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression. Journal of child and adolescent psychopharmacology. vol 31. issue 7. 2021-11-12. PMID:34324397. |
tolerability, safety, and effectiveness of two years of treatment with lurasidone in children and adolescents with bipolar depression. |
2021-11-12 |
2023-08-13 |
Not clear |
| Chun-Yi Su, Wei-Tse Hsu, Ching-Hua Li. Bilateral pedal edema associated with lurasidone: a case report. International clinical psychopharmacology. vol 36. issue 1. 2021-10-04. PMID:33230023. |
lurasidone, an atypical antipsychotic, is currently approved for treatment of schizophrenia and bipolar depression. |
2021-10-04 |
2023-08-13 |
Not clear |
| S S Nair, C J M Chua, D C L Te. Lurasidone-Induced Manic Switch in an Adolescent with Bipolar I Disorder: a Case Report. East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan. vol 31. issue 3. 2021-10-04. PMID:34588318. |
lurasidone is used for treatment of bipolar depression in adults and adolescents. |
2021-10-04 |
2023-08-13 |
Not clear |
| Manpreet K Singh, Andrei Pikalov, Cynthia Siu, Michael Tocco, Antony Loebe. Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: Journal of child and adolescent psychopharmacology. vol 30. issue 10. 2021-09-23. PMID:32392455. |
lurasidone in children and adolescents with bipolar depression presenting with mixed (subsyndromal hypomanic) features: |
2021-09-23 |
2023-08-13 |
Not clear |